This article focuses on the diagnosis and management of neuromyelitis optica spectrum
disorder (NMOSD). NMOSD is an autoimmune, demyelinating condition characterized by …

Background Multiple sclerosis (MS) is an autoimmune disease characterized by chronic,
progressive neurodegeneration of the central nervous system (CNS), and it is the most common …

Multiple sclerosis (MS) most commonly presents in young adults, although 3–5% of patients
develop MS prior to the age of 18 years. The new and comprehensive consensus for the …

For the past 10 years, disease-modifying therapy (DMT) options for multiple sclerosis (MS)
have grown remarkably where DMTs have been shown to reduce the risk of MS relapses. MS …

Background: Alemtuzumab is a humanized anti-CD 52 monoclonal antibody approved as a
disease-modifying therapy for active relapsing-remitting Multiple Sclerosis (MS). …

Tacrolimus is an immunosuppressant agent utilized for solid organ transplantations. It has
been associated with rare neurotoxic effects. This case highlights one possible delayed …

Patients with isolated neurosarcoidosis (NS) can present with neurological symptoms that
mimic other neurologic conditions, such as multiple sclerosis (MS). In this article, we present a …

This review article addresses the complex issues faced by individuals with Multiple Sclerosis
(MS) who are planning a family, becoming pregnant, or wishing to breastfeed their baby. …

Background In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly
improved clinical and MRI outcomes versus subcutaneous interferon beta-1a over 3 years in …

Multiple sclerosis (MS) is a disease of the central nervous system (CNS) that is the result of
the body's own immune cells being auto-reactive to the myelin regions of the body as if these …